Compare Gilead Sciences, Inc. (GILD) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Wayfair Inc — how do they compare? Gilead Sciences, Inc. trades at $134.63 (market cap $163.51B), while Wayfair Inc trades at $91.03 (market cap $12.10B). The key difference: Gilead Sciences, Inc. is far larger — about 13.5× Wayfair Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Wayfair Inc pays none. Which is the better fit depends on your goals.
| GILD | W | |
|---|---|---|
Market Cap | $163.51B | $12.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $119.05 |
52-Week Low | $108.22 | $55.38 |
Enterprise Value | $178.05B | $14.67B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Wayfair (W) trades at $93.74, up 5.63% today, with bullish technical signals from moving averages and a consensus analyst price target of $93.58. The company reported revenue of $12.46B in 2025 but a net loss of $313M, though recent quarters show earnings beats. Positive cash flow from operations of $534M supports liquidity, while expansion into brick-and-mortar stores and AI integration highlight strategic growth initiatives.
The outlook is cautiously optimistic with strong analyst buy ratings (51.78%) and momentum from recent sales events, but risks include persistent net losses, high debt-to-asset ratio of 95.11%, and competitive e-commerce pressures. Upside potential exists if profitability improves, but investors should monitor execution on physical store expansion and cost management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
